New cDAT application for for automated quantification of DAT SPECT images further extends Combinostics’ solutions across the entire patient pathway for neurological disorders and supports end-to-to-end workflows
New cPET application for amyloid and FDG brain PET quantification further extends Combinostics’ solutions across the entire patient pathway for neurological disorders and supports end-to-to-end workflows.
New cPET application for amyloid and FDG brain PET quantification further extends Combinostics’ solutions across the entire patient pathway for neurological disorders and supports end-to-to-end workflows
Stockholm, 14 June 2023 – Today, partners of the PROMINENT project announced the launch of…
cMRI is now available through TeraRecon's Eureka Clinical AI platform, an AI solution for imaging analysis spanning neurology, oncology, pulmonology, and cardiology.
New and existing tools, including cPET, cARIA, and the Dementia Differential Analysis report, extend Combinostics’ solution beyond neurological image quantification and support end-to-end workflows.
Fountain Health announces 100 percent coverage of Combinostics cMRI and cDSI. The company is now the first and only health insurance platform to provide complete coverage for the AI-enabled neurological imaging and decision support solutions.
Dr. Erik Post and Dr. Hans-Peter Huber have joined Combinostics as Group Chief Financial Officer (CFO) and Vice President of European Sales, respectively. Their contributions include considerable experience scaling software solutions.
cNeuro® cDSI™ and cNeuro cMRI™ achieve EC-certification under MDR, ensuring continued delivery of services to European customers.
The latest version of cNeuro® includes the launch of the Dementia Differential Analysis report, new disease-specific reports, additional automated MRI quantifications and imaging biomarkers, and more.
Combinostics US Inc.
177 Huntington Ave
17th Floor
Boston, MA 02115, USA
© Combinostics | Privacy Policy
